Neale S D, Smith R, Wass J A, Athanasou N A
Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford, UK.
Bone. 2000 Sep;27(3):409-16. doi: 10.1016/s8756-3282(00)00345-8.
A characteristic feature of Paget's disease is an increase in the number of osteoclasts in bone. Osteoclasts are formed from mononuclear phagocyte precursors that circulate in the monocyte fraction of peripheral blood. These cells require the presence of RANK ligand (RANKL)-expressing osteoblastic cells and human macrophage colony-stimulating factor (M-CSF) to form osteoclasts in vitro. To determine the role of osteoclast differentiation from circulating precursors in Paget's disease, we cultured monocytes from Paget's patients and gender- and age-matched normal controls with no evidence of bone disease for up to 21 days in the presence of UMR 106 cells and various concentrations of M-CSF (1-25 ng/mL) and 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] (10(-10) to 10(-7) mol/L). Relative to controls, there was a significant increase in the extent of osteoclast differentiation from pagetic monocytes as assessed by expression of tartrate-resistant acid phosphatase (TRAP), vitronectin receptor (VNR), and lacunar bone resorption. Serial dilution experiments (2 x 10(5) to 2 x 10(2) cells/well) showed no difference in the concentration of osteoclast precursors in the peripheral blood. In Paget's patients with high serum alkaline phosphatase (sAP) levels, increased sensitivity to the osteoclastogenic effect of 1,25(OH)(2)D(3) was noted. Osteoclast differentiation did not occur when M-CSF was substituted by interleukin-6 (IL-6) and soluble IL-6 receptor (sIL-6R), and these factors did not stimulate osteoclast differentiation in the presence of M-CSF. In this in vitro coculture system, osteoclast formation was inhibited by osteoprotegerin in a dose-dependent manner. In the presence of RANKL (5-30 ng/mL) and M-CSF (25 ng/mL), osteoclast formation and bone resorption were significantly increased in cultures of monocytes from patients with high and low sAP levels as compared with normal controls. Our findings suggest that the increase in osteoclast numbers seen in Paget's disease results not from an increase in the number of circulating precursors in peripheral blood but rather from an increased sensitivity of osteoclast precursors to the humoral factors, 1,25(OH)(2)D(3) and RANKL, which regulate osteoclast formation.
佩吉特病的一个特征性表现是骨中破骨细胞数量增加。破骨细胞由在外周血单核细胞部分循环的单核吞噬细胞前体形成。这些细胞在体外形成破骨细胞需要表达核因子κB受体活化因子配体(RANKL)的成骨细胞和人巨噬细胞集落刺激因子(M-CSF)的存在。为了确定循环前体来源的破骨细胞分化在佩吉特病中的作用,我们将佩吉特病患者以及无骨病证据的性别和年龄匹配的正常对照的单核细胞,与UMR 106细胞以及不同浓度的M-CSF(1 - 25 ng/mL)和1,25 - 二羟基维生素D3 [1,25(OH)2D3](10-10至10-7 mol/L)一起培养长达21天。与对照组相比,通过抗酒石酸酸性磷酸酶(TRAP)、玻连蛋白受体(VNR)的表达以及陷窝骨吸收评估发现,佩吉特病单核细胞来源的破骨细胞分化程度显著增加。系列稀释实验(2×105至2×102个细胞/孔)显示外周血中破骨细胞前体的浓度没有差异。在血清碱性磷酸酶(sAP)水平高的佩吉特病患者中,观察到对1,25(OH)2D3的破骨细胞生成作用的敏感性增加。当用白细胞介素-6(IL-6)和可溶性IL-6受体(sIL-6R)替代M-CSF时,破骨细胞分化未发生,并且在存在M-CSF的情况下这些因子也不刺激破骨细胞分化。在这个体外共培养系统中,骨保护素以剂量依赖性方式抑制破骨细胞形成。在存在RANKL(5 - 30 ng/mL)和M-CSF(25 ng/mL)的情况下,与正常对照相比,sAP水平高和低的患者的单核细胞培养物中破骨细胞形成和骨吸收均显著增加。我们的研究结果表明,佩吉特病中所见的破骨细胞数量增加并非源于外周血中循环前体数量的增加,而是源于破骨细胞前体对调节破骨细胞形成的体液因子1,25(OH)2D3和RANKL的敏感性增加。